Retatrutide, a novel dual agonist of the GLP-1 receptor and glucose-dependent insulinotropic polypeptide (GIP) receptor , is demonstrating promising outcomes in early patient studies. Ongoing examination https://shopretatrutidepeptide.com/retatrutide-research-knowledge-hub/